Inventor · disambiguated record

Tao Pei

Also filed as: PEI TAO

44 granted patents·30 pending applications·137 citations·filing 2004–2025

97Inventor score

Technology areasC12N A61P A61K A23L C07C

Files withARROWHEAD PHARMACEUTICALS INC59 INT FLAVORS & FRAGRANCES INC6 DEWIS MARK L2 SIRNA THERAPEUTICS INC2 BARRETT STEPHANIE E1

Top patents by PatentIndex Score

74 records

0196US10450565B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 22, 2019·15 cites·39 claims
0295US11884920B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Jan 30, 2024·2 cites·21 claims
0395US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
0494US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
0594US11214801B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·3 cites·30 claims
0693US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
0793US10597657B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·6 cites·51 claims
0892US11629349B2RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Apr 18, 2023·3 cites·14 claims
0992US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
1092US11549112B1RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 10, 2023·3 cites·14 claims
1192US11203756B2Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Dec 21, 2021·5 cites·25 claims
1292US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
1392US10294474B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted May 21, 2019·15 cites·50 claims
1492US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
1592US9238604B2Process and intermediates for preparing macrolactamsXU FENG·Filed 2012·Granted Jan 19, 2016·9 cites·8 claims
1691US7794768B2Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositionsINT FLAVORS & FRAGRANCES INC·Filed 2008·Granted Sep 14, 2010·6 cites·18 claims
1789US11174481B2Targeting ligandsARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 16, 2021·3 cites·4 claims
1887US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
1986US11845937B2RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Dec 19, 2023·1 cites·22 claims
2086US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
2186US9540639B2Tetragalnac containing conjugates and methods for delivery of oligonucleotidesSIRNA THERAPEUTICS INC·Filed 2013·Granted Jan 10, 2017·10 cites·22 claims
2286US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
2385US12365899B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·22 claims
2484US2024141351A1Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
2583US8987377B2Poly(amide) polymers for the delivery of oligonucleotidesBARRETT STEPHANIE E·Filed 2011·Granted Mar 24, 2015·7 cites·18 claims
2681US10590416B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 17, 2020·1 cites·52 claims
2780US12110492B2RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Oct 8, 2024·0 cites·14 claims
2880US7615661B2Thioester compounds and their use in fragrance or flavor applicationsINT FLAVORS & FRAGRANCES INC·Filed 2008·Granted Nov 10, 2009·1 cites·8 claims
2980US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
3079US12378558B2RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2024·Granted Aug 5, 2025·0 cites·19 claims
3177US2022064646A1RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
3276US12116573B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Oct 15, 2024·0 cites·3 claims
3376US11492624B2RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·1 cites·21 claims
3476US2023139166A1RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
3576US2023125671A1RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
3675US2025034577A1RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3771US7541055B2Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositionsINT FLAVORS & FRAGRANCES INC·Filed 2005·Granted Jun 2, 2009·2 cites·13 claims
3871US2025340877A1RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
3971US2022090077A1RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
4069US12173086B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 24, 2024·0 cites·15 claims
4169US11214802B2RNAi agents for inhibiting expression of alpha-ENaC and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·0 cites·42 claims
4269US2024392292A1RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
4369US2020263179A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
4468US12503696B2RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2024·Granted Dec 23, 2025·0 cites·16 claims
4568US8007849B2Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositionsINT FLAVORS & FRAGRANCES INC·Filed 2005·Granted Aug 30, 2011·1 cites·16 claims
4667US2022033817A1Targeting LigandsARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
4766US12441756B25′-cyclo-phosphonate modified nucleotidesARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Oct 14, 2025·0 cites·16 claims
4866US12442002B2RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
4966US12054718B2RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Aug 6, 2024·0 cites·34 claims
5066US8075937B2Alkyldienamides exhibiting taste and sensory effect in flavor compositionsDEWIS MARK L·Filed 2009·Granted Dec 13, 2011·0 cites·6 claims

Showing the top 50 of 74 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Tao Pei files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →